Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of low doses of alemtuzumab
and rituximab are effective in the treatment of patients with autoimmune cytopenias who has
failed on steroids, relapsed after steroids withdrawal or required continuous steroids
treatment.